Minimal Effective Concentration (EC90) of Ropivacaine

• Status: Completed
• Trial end date: 2020-05-04
• Target enrollment: 0
• Participant gender: All

Summary

Prospective up and down sequential evaluation of the minimal effective concentration of perineural ropivacaine for 90% success in axillary brachial plexus block with the injection of intravenous dexamethasone or saline placebo during regional anesthesia performance

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Besancon
• Treatments: BB 1101; Dexamethasone; Dexamethasone acetate; Ropivacaine

Criteria

Inclusion Criteria:

• 18 years old or older

• ASA Score 1,2 et 3 (American Society of Anesthesiologists Score)

• surgery under axillary brachial plexus block

• signed information consent

Exclusion Criteria:

• pregnancy and breastfeeding

• contraindication to regional anesthesia or technical impossibility

• impaired coagulation

• delay of surgery to short to allow regional anesthesia

• dementia or under administrative supervision

• allergy and contraindication to dexamethasone or ropivacaine

• total dose of ropivacaine higher than 3 mg / kg (recommended dose for upper limb regional anesthesia)

• opioids or pain killers abuse or addiction

• steroids consumption in the past 6 months

• surgery estimated to be greater than 4 hours

• anticipated bad observation of treatment

• patient enrolled in another trial